BioCardia (NASDAQ:BCDA) Upgraded at Alliance Global Partners

Alliance Global Partners upgraded shares of BioCardia (NASDAQ:BCDA) from a hold rating to a strong-buy rating in a research note released on Thursday morning,Zacks.com reports.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of BioCardia in a report on Wednesday, December 18th.

BioCardia Trading Up 6.5 %

BCDA stock opened at $2.47 on Thursday. The firm has a 50-day moving average of $2.20 and a two-hundred day moving average of $2.51. The company has a market cap of $11.31 million, a price-to-earnings ratio of -0.59 and a beta of 1.26. BioCardia has a 12 month low of $1.63 and a 12 month high of $8.85.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.